Results 161 to 170 of about 47,533 (300)

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. [PDF]

, 2017
Cancer aggressiveness may result from the selective pressure of a harsh nutrient-deprived microenvironment. Here we illustrate how such conditions promote chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). Glucose or glutamine withdrawal
Blanco, Fernando F, Brody, Jonathan R., Chand, Saswati N., Cozzitorto, Joseph A., Dukleska, Katerina, Jiang, Wei, Jimbo, Masaya, Lal, Shruti, Londin, Eric R., Mambelli-Lisboa, Nicole C., Metallo, Christian M., Moffat, Cynthia, Nevler, Avinoam, Parker, Seth J., Seifert, Erin L., Vaziri-Gohar, Ali, Winter, Jordan M., Yeo, Charles J., Zarei, Mahsa   +18 more
core   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

The Role of N6‐Methyladenosine Modification in Health and Disease

MedComm, Volume 7, Issue 6, June 2026.
N6‐methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotes, acting as a pivotal epitranscriptomic regulator of RNA metabolism. This modification plays a dual role: it maintains physiological homeostasis under normal conditions but drives disease progression when dysregulated.
Linghuan Li, Yuanhai Sun, Wanfang Zheng, Lingqin Li, Yaqian Feng, Minyou Qi, Hanbing Li   +6 more
wiley   +1 more source

Long noncoding RNA <em>CRNDE</em> functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer

, 2017
Hongyan Gao, Xiaodi Song, Ting Kang, Baohong Yan, Feng Li, Li Gao, Liang Ai, Xiaoni Liu, Jie Yu, Huiqi Li   +9 more
openalex   +2 more sources

IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway

, 2022
Chen Huang, Tao Zhou, Lihua Ma, Shipeng Zhao   +3 more
openalex   +2 more sources

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

MedComm, Volume 7, Issue 6, June 2026.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by unleashing antitumor immunity. This review comprehensively examines the molecular mechanisms underlying key immune checkpoints—including PD‐1/PD‐L1, CTLA‐4, and TIM‐3—and their clinical applications.
Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai   +9 more
wiley   +1 more source